Identification of fatty acid amide hydrolase as a metastasis suppressor in breast cancer

Clinical management of breast cancer (BC) metastasis remains an unmet need as it accounts for 90% of BC-associated mortality. Although the luminal subtype, which represents >70% of BC cases, is generally associated with a favorable outcome, it is susceptible to metastatic relapse as late as 15 years after treatment discontinuation.

Citation:
Tundidor I, Seijo-Vila M, Blasco-Benito S, ……. Andradas C, Manzano S, Álvarez-López I, et al. Identification of fatty acid amide hydrolase as a metastasis suppressor in breast cancer. Nat Commun. 2023;14(1)

Keywords:
Amidohydrolases; biomarkers; tumor; fatty-acid amide hydrolase; gene; nucleotide

Abstract:
Clinical management of breast cancer (BC) metastasis remains an unmet need as it accounts for 90% of BC-associated mortality. Although the luminal subtype, which represents >70% of BC cases, is generally associated with a favorable outcome, it is susceptible to metastatic relapse as late as 15 years after treatment discontinuation.